Researchers shed light on the "dark matter" of the gut, revealing a species of fungus that could potentially help counter ...

GSK will buy efimosfermin, a liver disease drug in late-stage trials, for up to $2 billion from U.S. biotechnology firm ...

A groundbreaking study from the University of Oklahoma reveals that the hormone FGF21 can reverse fatty liver disease by ...

New research reveals that semaglutide significantly improves liver health in MASH patients. A new study published in the New ...

GSK acquires Boston Pharmaceuticals' efimosfermin for up to $2 billion, targeting liver diseases like MASH and ALD.

With its purchase of Boston Pharmaceuticals' drug, GSK extends a streak of dealmaking it's undertaken to build a liver ...

GSK is set to acquire efimosfermin, a promising liver disease drug, from Boston Pharmaceuticals for a potential $2 billion.

Just a day after dropping a $625m cancer asset, GSK has inked a deal worth a potential $2bn to acquire Boston Pharmaceuticals ...

GSK plans to purchase an experimental drug for the liver disease MASH from Boston Pharmaceuticals for $1.2 billion upfront.

Under the agreement, GSK will acquire BP Asset IX, a subsidiary of Boston Pharmaceuticals, for up to $2 billion in total cash ...

GSK has agreed to pay $1.2 billion upfront to acquire rights to efimosfermin from Cambridge, Massachusetts-based Boston ...